Bullish Case: At $1.745 after a ~40% monthly drawdown, ABOS now prices severe pessimism. Dec-26/Jan-27 $5 calls (IV ~310-375%, delta ~0.55, $0.85 ask) imply the market still assigns meaningful probability of a >180% re-rate on a positive ALTITUDE-AD sabirnetug topline or partner/deal headline. The contango term structure keeps late-2026 event convexity alive from a washed-out base.

Bearish Case: The -39.6% month and -16.9% week suggest the negative-readout/dilution path my earlier forecasts weighted may already be partially materializing. Historical return surface holds mass at -70% to -85% multi-period returns; put IVs (Jan-27 $2.5P at 500%) price continued gap-down risk. Cash runway into 2027 and a likely ATM raise cap any rally.

Potential Outcomes:

1. 30% Further decline/financing: dilution PR or weak data follow-through → $1.00-1.50 (falsifiable via offering 8-K).
2. 28% Dead-cat stabilize: rangebound $1.50-2.20, episodic volume spikes.
3. 22% Positive late-2026 topline/safety → re-rate toward $3.50-5 (falsifiable via topline PR, $5C bid >$2).
4. 12% Partner/M&A announced → $3-4+ quickly.
5. 8% Squeeze/macro biotech bounce: transient +50-100%, fades.

SPY vol surface (~15-20 ATM, steep downside skew) is benign; ABOS-specific events dominate. My Sept 15 'no binary news' 25% weight was invalidated by the crash—overweighting stability; negative-path weights were directionally right.

October 15, 2026